Document is current

Article History

Received: 16 April 2025

Accepted: 11 July 2025

First Online: 23 July 2025

Declarations

:

: YM: Has been a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. YUchihashi: no conflict of interest. YInagaki: Has grants or research support from Chugai Pharmaceutical Co., Ltd., and Olympus Co., Ltd. MO: no conflict of interest. YUchihara: no conflict of interest. NS: no conflict of interest. YIshida: no conflict of interest. YK: no conflict of interest. AS: Has been a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd. KN: Has been a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd; has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd; personal fees from F. Hoffmann-La Roche Ltd; grants, personal fees and non-financial support from Sysmex Co.; grants and personal fees from Takeda Pharmaceutical Co.; grants and personal fees from Sanofi S.A.; personal fees from CSL Behring Co.; grants and personal fees from KM Biologics Co.; grants and personal fees from Novo Nordisk A/S; grants and personal fees from Bayer AG; grants and personal fees from Bioverativ Inc; and grants and personal fees from Shire Plc; and is a co-inventor of a patent related to an anti‐FIXa/FX bispecific antibody. MS: Has been a member of Medicinal Biology of Thrombosis and Hemostasis established by Nara Medical University and Chugai Pharmaceutical Co., Ltd; has received research funding from Chugai Pharmaceutical Co., Ltd., CSL Behring, and Takeda; has received honoraria from Bayer, Chugai Pharmaceutical Co., Ltd., CSL Behring, Fujimoto Seiyaku, Sanofi, Novo Nordisk, Pfizer, and Takeda; holds patents with Chugai Pharmaceutical Co., Ltd.; and has participated on a data safety monitoring board or advisory board for Chugai Pharmaceutical Co., Ltd., Fujimoto Seiyaku, KYORIN Pharmaceutical Co., Ltd., Novo Nordisk, and Pfizer. N.S. has received honoraria from Bayer, Chugai Pharmaceutical Co., Ltd., CSL Behring, Japan Blood Products Organization, KM Biologics, Novo Nordisk, Pfizer, Sanofi, and Takeda. YT: Has grants from Chugai Pharmaceutical Co., Ltd. and Asahi Kasei Co., Ltd. AK: no conflict of interest.

: All participants were given a clear and comprehensive explanation of the study on the basis of the Declaration of Helsinki. Subsequently, participants signed informed consent forms. Ethical approval for the studies was obtained from both the Nara Medical University (ID: 2097) and Chugai Ethics Committees (ID: E19086).

: No identifiable participant information is provided in the manuscript, figures, or tables.